PELL Bio-Med Technology CoTPE:6949 13 EBIT per Share is NT$-7.71 as of Dec. 2025. GuruFocus rates TPE:6949 with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 1,173 Biotechnology companies, PELL Bio-Med Technology Co ranks worse than 79.97% on this metric.
PELL Bio-Med Technology Co's EBIT per Share for the
three
months ended in Dec. 2025 was NT$-2.95.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-7.71.
During the past 3 years, the average EBIT per Share Growth Rate was -10.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for PELL Bio-Med Technology Co's EBIT per Share or its related term are showing as below:
TPE:6949'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -10.1 Med: -8.8 Max: -7.5
Current: -10.1
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of PELL Bio-Med Technology Co was -7.50% per year. The lowest was -10.10% per year. And the median was -8.80% per year.
TPE:6949's 3-Year EBIT Growth Rate is ranked worse than 79.97% of 1173
companies
in the Biotechnology industry
Industry Median: 15.4
vs TPE:6949: -10.10
PELL Bio-Med Technology Co (TPE:6949) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
PELL Bio-Med Technology Co EBIT per Share Related Terms
PELL Bio-Med Technology Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-7.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PELL Bio-Med Technology Co (TPE:6949) has a EBIT per Share of NT$-7.71 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PELL Bio-Med Technology Co and its competitors. According to the industry distribution chart, PELL Bio-Med Technology Co ranks #938 out of 1173 companies in the Biotechnology industry, placing it in the top 80%.
Is PELL Bio-Med Technology Co's EBIT per Share too high?
PELL Bio-Med Technology Co's current EBIT per Share is NT$-7.71. Based on the distribution chart, PELL Bio-Med Technology Co ranks #938 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PELL Bio-Med Technology Co has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does PELL Bio-Med Technology Co's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PELL Bio-Med Technology Co ranks #938 out of 1173 companies for EBIT per Share. This places PELL Bio-Med Technology Co in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PELL Bio-Med Technology Co and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PELL Bio-Med Technology Co's current EBIT per Share is NT$-7.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PELL Bio-Med Technology Co stock overvalued right now?
PELL Bio-Med Technology Co (TPE:6949) has a current EBIT per Share of NT$-7.71. The current EBIT per Share is NT$-7.71. PELL Bio-Med Technology Co's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For PELL Bio-Med Technology Co (TPE:6949), the current EBIT per Share is NT$-7.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PELL Bio-Med Technology Co Ltd is a company engaged in the research and development and application of autologous T Cell Therapy (Adoptive T Cell Therapy), CAR-T (Chimeric Antigen Receptor T cell), and Gene-Modified Adipose-Derived Stem Cell (Gene-Modified Adipose-Derived Stem Cell). The company's segments includes Cell products, Consulting services, and Others.
13GF Score
Get the complete analysis for TPE:6949
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6949 has been successfully added to your 
